<DOC>
	<DOCNO>NCT01962376</DOCNO>
	<brief_summary>The investigator assess whether addition preoperative regimen Bevacizumab regimen improve R0 resection rate survival among patient potentially resectable gastric cancer liver metastasis .</brief_summary>
	<brief_title>Preoperative Chemotherapy With Bevacizumab For Potentially Resectable Gastric Cancer With Liver Metastasis</brief_title>
	<detailed_description>Groups 1 : Capecitabine Plus Oxaliplatin With Bevacizumab Patients With Potentially Resectable Gastric Cancer With Liver Metastasis . Groups 2 : Capecitabine Plus Oxaliplatin With placebo Patients With Potentially Resectable Gastric Cancer With Liver Metastasis . Group 1 compare Group 2 disease-free survival time . Stage I：Preoperative therapy Capecitabine Plus Oxaliplatin With Bevacizumab superior Capecitabine Plus Oxaliplatin alines . Stage II : therapy surgery Capecitabine Plus Oxaliplatin With Bevacizumab superior Capecitabine Plus Oxaliplatin alones surgery 6 month .</detailed_description>
	<mesh_term>Neoplasm Metastasis</mesh_term>
	<mesh_term>Neoplasms , Second Primary</mesh_term>
	<mesh_term>Stomach Neoplasms</mesh_term>
	<mesh_term>Liver Neoplasms</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<mesh_term>Oxaliplatin</mesh_term>
	<mesh_term>Capecitabine</mesh_term>
	<criteria>1.Pathological tissue gastric cancer gastric liver biopsy . 2.Immunohistochemistry confirm HER2 ( ) . 3.The number liver metastasis le 3 evey one less 5 cm . 4.Liver metastasis must clinically limited Type H1 Type H2 . 5.gastric cancer able resectable lesion T14a N12 M0 . 6.Patients•had receive radiotherapy past organ metastasis peritoneal metastasis . 7.Karnofsky performance status performance status &gt; 70 . 8.Inadequate hematopoietic function： Hemoglobin≥90g/L ; ANC≥1,500/mm3 ; Platelet≥100,000/mm3 9.Inadequate organ function define : Total bilirubin≤1.5 pper limit normal range ( ULN ) ; alanine transaminase / Aspertate aminotransferase≤2.5 upper limit normal range ( ULN ) ( ≤5.0 x ULN hepatic metastasis ) ; serum creatinine≤1.5 pper limit normal range ( ULN ) , Serum albumin≥30g/L . 10.expectancy must 3 month . 11.the random blood urine pregnancy test fertile woman must negative result pregnancy test 7 day . 12.Patients male female use reliable contraception contraceptive method end study 30 day later . Type H1 : one leaf liver metastasis . Type H2 : two leaf scatter metastatic liver . 1 . Patients extrahepatic metastasis Include peritoneal metastasis . 2 . Primary ulcerative type existence perforation . 3 . Patients malignancy 5 year . 4 . Patients severe liver disease , kidney disease , respiratory disease , uncontrolled diabetes severe infection . 5.Patients hypertension fail control , active bleeding , 3~4 proteinuria , heal wound , thromboembolism , heart failure , clinical symptom heart disease . 6.Patients obvious peripheral nervous system disorder , mental disorder disorder central nervous system history . 7.Patients history organ transplantation . 8.Patients medical psychiatric condition disease , investigator 's judgment , would make patient inappropriate entry study . 9.Patients combined antitumor drug outside research program .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>October 2013</verification_date>
	<keyword>Capecitabine</keyword>
	<keyword>Oxaliplatin</keyword>
	<keyword>Bevacizumab</keyword>
	<keyword>Potentially Resectable Gastric Cancer Liver Metastasis</keyword>
</DOC>